Ipca Laboratories Ltd
Add to watch list to get report alerts
BSE Code:
524494
NSE Code:
IPCALAB
Business Profile
Business Profile
Ipca Laboratories (IPCA), a recognized trading house, exports to over 108 countries. Over 60% of its turnover comes from specialty formulations such as anti-malarials, anti-emetics, anti-hypertensives, antibiotics and other drugs. The balance comes from bulk drugs, drug intermediates, generic formulations, hospital products, ..etc.
The company works out of its various divisions namely general pharma division, Intima division, Activa division, 3C division, Innova division and Hycare division. It is the largest Indian manufacturer of anti-malarial bulk drug chloroquine phosphate. The formulations manufacturing unit of the company in Athal, Silvassa is being expanded and upgraded to meet the growing formulations export business.
The company exports formulations as well as APIs to several Asian countries. The company markets branded formulations to Sri Lanka, Myanmar and Vietnam. During 2004-2005, the company introduced 15 new products in the domestic market. New products introduced during the last three financial years now constitute nearly 24% of its domestic formulations sales. The company is setting up new formulations manufacturing unit at the special economic zone (SEZ) Indore. IPCA currently has five wholly-owned overseas subsidiary companies after amalgamation of the wholly-owned subsidiary Innotech Pharma with the company.
The company plans to develop various APIs/intermediates having good potential for exports and local market. It plans additional investment in manpower, latest instrumentation to upgrade and strengthen R&D facilities. Also, the company aims at developing newer drug delivery systems along with developing formulations for developed market and bio-equivalence studies of the same.
Financials
The company announced a steep drop in standalone net profit for the quarter ended December 2008. During the quarter, the profit of the company declined 39.54% to Rs 231.80 million from Rs 383.40 million in the same quarter last year. Net sales for the quarter rose 11.19% to Rs 3,133.10 million, while total income for the quarter rose 11.07% to Rs 3,136.30 million, when compared with the prior year period. It reported earnings of Rs 9.24 a share during the quarter, registering 39.53% decline over prior year period.
Recent Developments
07-APR-09
The company received a final approval for marketing Hydrochlorothiazide Capsule in the strength of 12.5 mg from the United States Food and Drug Administration (USFDA).